Background Patients with sickle cell anemia (SCA) have an increased prevalence of nephropathy and mortality from chronic kidney disease (CKD). Methods We evaluated the association of hyperuricemia and nocturnal hypertension with lower estimated glomerular filtration rate (eGFR) using cystatin-C in patients aged 10-21 years with the HbSS or HbSB0 form of the disease during a nonacute clinic visit. eGFR and uric acid measurements were obtained in 83 and 81 participants, respectively, and 24-h ambulatory blood pressure monitoring (ABPM) was performed in 44 participants. Annual testing included vital signs, complete blood count, comprehensive metabolic panel, medications, urine microalbumin/creatinine, and lactate dehydrogenase measurements. Hyperuricemia was defined as a uric acid level of ≥5.5 mg/dL. Nocturnal hypertension was defined as >25% of nocturnal readings at >95th percentile according to norms established by the American Heart Association Statement on ABPM in children and adolescents. Results The mean eGFR was statistically significantly lower in patients with hyperuricemia than in those with normal uric acid levels (143 vs. 161 mL/min/1.73 m 2 , respectively). Of the 44 participants for whom ABPM data were available, 14 (32%) had systolic nocturnal hypertension and 12 (27%) had diastolic nocturnal hypertension. The mean eGFR was statistically significantly lower in participants with nocturnal systolic and diastolic hypertension than in those with normal nocturnal blood pressure. In a regression model, nocturnal hypertension and hyperuricemia were associated with a lower eGFR. Conclusions Two risk factors for CKD, i.e., nocturnal hypertension and hyperuricemia, were associated with lower eGFR in older children and adolescent patients with SCA. Longterm studies on their association with progression to CKD in this population are warranted. Key point Nocturnal hypertension and hyperuricemia are established risk factors for nephropathy in other diseases and may play a role in SCA nephropathy.
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Introduction
Patients with sickle cell anemia (SCA) can develop renal injury at an early age and progress to death from renal failure [1] [2] [3] . While approaches to estimate glomerular filtration rate (eGFR) have changed over time, data suggests that infants with SCA develop a hyperfiltration phase which plateaus during childhood [4] [5] [6] . During adolescence, eGFR begins to decline in some patients, and around 10% of adolescent patients with SCA develop a GFR of <90 mL/min/1.73 m 2 [5, 7, 8] . Progression to chronic kidney disease (CKD) and renal failure in adults with SCA is devastating, with 10-20% of all deaths in SCA patients associated with kidney disease and 30% of SCA deaths from irreversible organ failure complicated by renal failure [9] [10] [11] . Adult patients with the homozygous form of the disease (HbSS) develop renal failure at an earlier age (median 23.1 years) than adult patients with hemoglobin SC (HbSC; median 49.9 years). The mean survival of SCA patients after developing end-stage renal disease is less than 3 years, and dialysis and renal transplant outcomes in patients with SCA are poor [2, 3, 12] .
While it is clear that many young adult patients with SCA develop a decline in their eGFR and progress to CKD, current studies fail to identify consistent risk factors and interventions that modify disease progression [13, 14] . Nocturnal hypertension and hyperuricemia are well-established, independent risk factors for cardiovascular disease and progression to CKD in children without SCA [15] [16] [17] [18] [19] . Ambulatory blood pressure monitoring (ABPM), which identifies nocturnal hypertension, is superior to casual in-clinic blood pressure (BP) monitoring for identifying children at high risk for end-organ damage [20] . Two prior studies have identified a high prevalence of nocturnal hypertension in patients with SCA, yet no data are available to define the association between nocturnal hypertension and eGFR in SCA [21, 22] . Hyperuricemia has been associated with hypertension and cardiovascular events in other diseases but, despite the high prevalence of hyperuricemia in SCA, the association of hyperuricemia and sickle cell nephropathy has not been explored [18, 19] . Hyperuricemia has been associated with leg ulcers and pulmonary hypertension in SCA [23] [24] [25] .
With the knowledge that adolescent SCA patients begin their decline in eGFR and the independent strong associations of nocturnal hypertension and hyperuricemia with progression to CKD in other diseases, we investigated our hypothesis that nocturnal hypertension and hyperuricemia are associated with lower eGFR in adolescent SCA patients [16] [17] [18] 20] . We also evaluated other clinical and laboratory variables that prior studies suggest may be associated with a lower eGFR [5, 8, 13, 14, [26] [27] [28] .
Methods
The Institutional Review Board at the University of Alabama at Birmingham (UAB) approved this study of the evaluation of risk factors for the progression to sickle cell nephropathy, and written consent and assent were obtained from every parent and child enrolled. In exploring the concept for a randomized controlled trial to correct abnormal nocturnal BP in adolescent patients with SCA, this study was performed to determine the association between nocturnal hypertension, hyperuricemia, as well as other laboratory results, and clinical information on eGFR in patients aged ≥10 years. All patients with HbSS or SB0 thalassemia (age > 5 years) who attend the Pediatric Sickle Cell Clinics at UAB/Children's of Alabama were eligible to enroll in this cohort study, but 24-h ABPM is deferred until patients are ≥10 years old. Participants were recruited during their routinely scheduled well-visits from either the hospital-based Pediatric SCA clinic in Birmingham, Alabama or at a UAB Pediatric SCA Satellite clinic.
All participants were expected to complete institutional standard of care annual testing that includes BP obtained by a DINAMAP device in a sitting position, a complete blood count with reticulocyte count, metabolic profile, urine studies [microalbumin/creatinine (Cr)], and lactate dehydrogenase (LDH). Uric acid was measured in the cohort as a study procedure. All blood and urine specimens were obtained and processed at the clinical laboratory at the University of Alabama/ Children's of Alabama or at the Satellite clinic laboratory during each patient's first non-acute SCA clinic visit after written consent/assent were provided. In-clinic systolic and diastolic hypertension was defined by a BP of >95th percentile for age, height, and sex [29] . GFR was estimated by serum cystatin C (eGFR) using the BN ProSpec System (Siemens Healthineers, Erlangen, Germany): log GFR = 1.962 + [1.123 × log (1/cystatin C)]. Microalbuminuria was defined as >30 mg/g Cr using a Siemens DCA Vantage Analyzer (Siemens Healthineers). Hyperuricemia was defined as a uric acid level of ≥5.5 mg/dL [30] . Testing for uric acid, urine microalbumin, and cystatin C were not performed at satellite SCA clinics. Of the 120 participants enrolled in the SCA Nephropathy cohort, 94 participants were aged ≥10 years. eGFR and uric acid levels were obtained in 83 and 81 participants, respectively, and 24-h ABPM was performed in 44 of the participants aged ≥10 years. A chart review was also performed to identify patient age, gender, vital signs, current SCA-modifying therapy (no therapy, chronic transfusion, or hydroxyurea).
Adolescent participants (age ≥10 years) were eligible to complete 24-h ABPM regardless of their current in-clinic BP. Participants who underwent ABPM had their monitor placed by the research team at the end of their non-acute SCA clinic visit. All ABPM procedures conformed to the 2014 American Heart Association (AHA) guidelines for cuff placement, monitoring, and quality assurance in children and adolescents [20] . Participants completed the monitoring and a self-report diary that included start and end times of activities and sleeping. As no established norms on ABPM exist for patients with SCA, we used the defined norms for 95th percentile BP for awake, sleeping, and 24-h BP norms based on age and gender percentile from the general population [20] . Nocturnal hypertension, as identified by BP load, was defined as >25% of nocturnal BP readings that were >95th percentile according to norms established by the American Heart Association Statement on ABPM in Children and Adolescents [20] . Percentage nocturnal dipping was defined as: (mean awake − mean sleeping BP) divided by mean awake BP. Attenuated nocturnal dipping was defined by <10% to ≥0% dip in mean BP while sleeping. Reverse dipping was defined by A <0% dip while sleeping (BP increased while sleeping). Among the 94 participants, 47 had ABPM placed and 44 completed ABPM per AHA guidelines for quality assurance (3 participants removed the BP cuff at night). Patients received a U.S. $25 payment upon completion of the ABPM.
Descriptive statistics were expressed as the mean and standard deviation (SD). Variables were compared between patients with and without nocturnal hypertension and those with and without hyperuricemia, and current SCA-modifying therapy using the t test for normally distributed continuous variables, Wilcoxon for non-normally distributed continuous variables, and chi-square for discrete variables. Analysis of variance (ANOVA) was used to compare differences in variables across categories of normal, attenuated, and reverse dip of systolic BP (SBP), as well as categorical variables of SCAmodifying therapy. If the ANOVA was statistically significant, Tukey's honest significant difference test was performed to further evaluate differences. Box plots were generated to compare the distribution of eGFR by hyperuricemia, SCAmodifying therapy, and nocturnal systolic hypertension. pvalues of <0.05 were considered to be statistically significant. The variables selected for regression modeling were based on biological plausibility for their association with eGFR. Stepwise forward linear regression was used to determine variables associated with eGFR, with a p value of <0.1 required to enter the model. All analyses were conducted using JMP version 10 (SAS Institute, Cary, NC) and SAS version 9.4 software (SAS Institute).
Results
The 94 participants evaluated in this study were between 10.0 and 21 years of age (mean ± SD 15.2 ± 3.0), of whom 86 had the HbSS form of the disease and eight had the sickle beta zero thalassemia (HbSB0) form. Fourteen participants (15%) were not receiving a SCA-modifying therapy, 37 (39%) were on hydroxyurea, and 43 (46%) were on transfusion therapy (24 on simple transfusion and 19 on exchange transfusions) [Electronic Supplementary Material (ESM) Table 1 ]. The most prevalent reasons for treatment among the 80 participants receiving an SCA-modifying therapy included central nervous system (CNS; n = 48) disease, pain (n = 21), and recurrent acute chest syndrome (n = 8). The mean eGFR for the cohort was 158.2 mL/min/1.73 m 2 ± 30.2. The maximum and minimum eGFR was 256 and 82 mL/min/1.73 m 2 , respectively.
Ambulatory blood pressure monitoring Among the 44 participants aged ≥10 years who completed 24-h ABPM, 32% had systolic nocturnal hypertension and 27% had diastolic nocturnal hypertension ( Table 1 ). The only variables that were statistically different between the 44 participants (≥10 years) who completed ABPM and the 50 additional participants in the cohort (10-21 years) who did not complete ABPM were hemoglobin (8.6 ± 1.4 vs. 9.5 ± 1.5 g/dL, respectively) and absolute neutrophil count (5618 ± 2315 vs. 4100 ± 2512 × 10 6 /L, respectively) (ESM Table 2 ).
Participants with systolic nocturnal hypertension had a lower eGFR than those without systolic nocturnal hypertension (140 ± 31 vs. 168 ± 30 mL/min/1.73 m 2 , respectively) ( Table 1 ). Higher hemoglobin and lower LDH levels were also associated with systolic nocturnal hypertension. In-clinic hypertension did not correlate with nocturnal hypertension; only three of the 14 (21%) participants with systolic nocturnal hypertension and four of the 12 participants with diastolic nocturnal hypertension were also identified as having an abnormal in-clinic BP. Furthermore, only two participants in our cohort had ambulatory daytime hypertension.
Attenuated nocturnal dipping and reverse nocturnal dipping were present in 31 of 44 participants (70%) for whom data on SBP were available. Participants with reverse nocturnal SBP dipping had a lower eGFR (134 ± 31 mL/min/1.73 m 2 ) than those with attenuated nocturnal dipping (160 ± 24 mL/min/1.73 m 2 ) and normal nocturnal dipping (177 ± 33 mL/min/1.73 m 2 ). Lower platelet count (p = 0.03) was also associated with abnormal systolic nocturnal dipping (Table 1) .
Hyperuricemia The mean uric acid for 81 participants in this study was 4.9 (SD 1.5) mg/dL. Twenty-four participants (30%) had hyperuricemia. Participants with hyperuricemia had a statistically significantly lower eGFR than those with a normal uric acid (143 ± 23 vs. 161 ± 31 mL/min/1.73m 2 , respectively; p = 0.02) (Fig. 1a) . Among participants with normal nocturnal SBP, those with hyperuricemia (≥5.5 mg/ dL) had a lower eGFR than participants with normal uric acid (143 ± 29 vs. 176 ± 30 mL/min/1.73 m 2 , respectively; p = 0.02) (Fig. 1c) . No statistical difference was noted in eGFR among participants based on sickle cell diseasemodifying therapy overall or when stratified by nocturnal hypertension (Fig. 1b, d ).
Microalbuminuria We identified no statistical relationship between ABPM and microalbuminuria. Of the 14 (21%) participants with systolic nocturnal hypertension three had microalbuminuria, as did eight of 29 (28%) patients without nocturnal systolic hypertension (p = 0.7). Two of ten (20%) patients with reverse systolic dipping also had microalbuminuria, three of 18 (14%) patients with attenuated systolic dipping had microalbuminuria, and six of 12 patients with normal nocturnal dipping had microalbuminuria (p = 0.08). For all participants aged ≥10 years, we also identified no statistical difference in prevalence of microalbuminuria by hyperuricemia; six of 22 (27%) patients with hyperuricemia also had microalbuminuria and 12 of 55 (22%) patients with normal uric acid had microalbuminuria (p = 0.6).
Sickle cell disease-modifying therapy Participants on hydroxyurea therapy had lower white blood cell counts than those on no disease-modifying therapy or chronic transfusion (ESM Table 1 ). Participants on chronic transfusion had higher hemoglobin and lower LDH levels than participants on hydroxyurea or no disease modifying therapy (ESM Table 1 ). Uric acid levels were statistically lower among participants on chronic transfusion (4.4 mg/dL) than among those on hydroxyurea therapy (5.3 mg/dL) or no therapy (5.6 mg/dL) (p = 0.01) (ESM Table 1 ). Clinic blood pressure was not significantly different based on SCA-modifying therapy. However, based on ABPM, patients on chronic transfusion had higher nocturnal SBP and diastolic BP (DBP), and lower SBP and DBP dip than patients on hydroxyurea therapy or no therapy.
Regression modeling
We conducted linear regression modeling to evaluate risk factors for lower eGFR. Among all statistically significant laboratory and 24-ABPM variables analyzed in stepwise regression, only dichotomous variables of abnormal nocturnal blood pressure load (p = 0.001) and hyperuricemia (p = 0.006) were associated with lower eGFR (Table 2) . Elevation in white blood cell count was entered into the final model but did not reach statistical significance (p = 0.09).
Discussion
Patients with SCA are at high risk of morbidity and mortality associated with sickle cell nephropathy. Early identification of patients at risk for progressive disease and developing interventions to prevent progression are vital to enhancing the longevity and quality of life of patients with SCA. As nocturnal hypertension and hyperuricemia are wellestablished risk factors for the development of CKD in non-SCA populations, the study cohort reported here was designed to analyze these risk factors in adolescent SCA patients, as this age group is the first to experience declining eGFR [5] . At cohort entry, SCA patients identified with nocturnal hypertension and hyperuricemia had a markedly lower eGFR. Of interest to patients and clinicians, both of these risk factors (hypertension and hyperuricemia) have U.S. Federal Drug Administration-approved interventions that can be tested in an SCA clinical trial.
The identification of hypertension in patients based on clinic BP suggests a risk for sickle cell nephropathy in adults [13, 31] . Clinic hypertension has also been identified as a risk factor for both overt and silent strokes [32] [33] [34] . While inclinic BP is convenient and may portend clinical complications, the gold standard strategy for identifying risk for endorgan damage in other diseases has been to perform 24-h ABPM [20] . The results from our cohort study confirms those of prior pediatric studies that demonstrate a lack of correlation between hypertension defined by in-clinic BP monitoring and 24-h ABPM [21, 35] . In addition, our cohort mirrors the results of two prior studies which suggested that SCA patients have a higher prevalence of nocturnal hypertension and that pediatric SCA patients lack nocturnal dipping [21, 22] . The prevalence of non-dipping in our SCA study (70% abnormal SBP dipping and 50% abnormal DBP dipping) is higher than that observed in obese pediatric patients (42 and 17% abnormal SBP and DBP dipping, respectively) or patients with diabetes (20-40% abnormal dipping) [36] [37] [38] . Finally, the results of our study suggest that nocturnal hypertension and abnormal nocturnal dipping have strong associations with a lower eGFR (33 mL/min/1.73 m 2 lower for patients with nocturnal hypertension) and may be, as has been wellestablished in several other disease states, a strong predictor of adverse renal and cardiovascular outcomes. A second important finding derived from our data is the association of and potential causal role for hyperuricemia on progression to SCA nephropathy and hypertension. Hyperuricemia in SCA patients has been associated with leg ulcers and pulmonary hypertension [24, 25] . In non-SCA pediatric and adult populations, hyperuricemia has been associated with a decrease in eGFR and progression to CKD [17, 39, 40] . Our data independently link hyperuricemia to eGFR and predict that a uric acid level of ≥5.5 mg/dL lowers eGFR by 28 mL/min/1.73m 2 . Animal models suggest a casual role of hyperuricemia on progression to CKD. Hyperuricemia in animals leads to an initial phase of hypertension that is reversible due to increased renal release and reduction in plasma nitric oxide; the second, irreversible phase is associated with vascular smooth muscle proliferation and inflammation, which leads to arteriosclerosis causing chronic hypoperfusion, tubulointerstitial inflammation, and fibrosis [18] . As SCA patients have known abnormalities of their endothelial system, an increase in uric acid that exacerbates endothelial dysfunction could also contribute to progression to SCA nephropathy. In addition to its potential direct effect on CKD, uric acid has become a well-established risk factor for hypertension in children without SCA, and uric acid reduction can ameliorate elevations in BP [18, 41] . If additional studies confirm that hyperuricemia contributes to hypertension and progression to CKD in SCA, early introduction of medications that reduce uric acid should be evaluated prospectively in future pediatric SCA clinical trials.
We did not demonstrate a protective role for hydroxyurea or blood transfusion in this cross-sectional study but will continue to evaluate these participants prospectively. One potential concerning finding is that the group receiving monthly blood transfusion had a significantly higher percentage of patients with nocturnal hypertension and nocturnal dipping. As a convenience sample was used for the current study, participants had ABPM performed after their clinic visit, which included either simple transfusion or red cell exchange transfusion. We could postulate that transfusion volume accounted for this hypertension. However, only one of 21 patients (5%) were identified with ambulatory daytime hypertension after their transfusion as compared to 12 patients (57%), with nocturnal hypertension after transfusion and an additional 16 transfusion patients (76%) having an increase in BP while sleeping. An alternative concern for the transfusion patients would be the hypothesis that patients on chronic transfusion have suffered a more severe clinical course that includes kidney damage. Similar to patients on chronic transfusion for stroke who, despite strict hemoglobin S (HbS) control, continue to develop CNS vasculopathy and new strokes, these patients may represent a subset of patients who may require novel therapies or SCA transplant to prevent continued organ damage [42, 43] .
Some pediatric SCA studies have identified an association between in-clinic BP and microalbuminuria, but many other studies have failed to replicate this association [5, 13, 14, 28] . We did not demonstrate an association of nocturnal hypertension or hyperuricemia with microalbuminuria. In a large non-SCA adult ABPM registry of almost 100,000 patients, nocturnal hypertension was associated with albuminuria [44] . As only 20% of our pediatric cohort were identified with microalbuminuria at the time of their study visit but up to 70% of adults develop microalbuminuria, we may eventually identify an association between nocturnal hypertension and progression to proteinuria or microalbuminuria over time [45] . In large studies of hyperuricemia, abnormal uric acid level has a greater impact on development of CKD, defined by eGFR, than albuminuria [17, 46] . This study has a number of limitations worth noting. First, not all participants completed 24-h ABPM and the ABPM has not yet been repeated to confirm the reproducibility of nocturnal hypertension and nocturnal dipping. While the reproducibility of nocturnal hypertension is high in pediatric populations, nocturnal blood pressure dipping has a lower reproducibility [47] . Second, our data identify a lower eGFR in patients with abnormal nocturnal hypertension and abnormal uric acid, but those eGFR values may be within the normal range. While we are hypothesizing that similar to the strong evidence in non-SCA diseases that links nocturnal hypertension and abnormal uric acid to CKD there is a similar link in SCA, this latter link has not yet been proven. Future studies are needed to determine if these risk factors for lower eGFR are also associated with continued progression to CKD. Third, we used cystatin C to estimate GFR, rather than nuclear medicine techniques. While we acknowledge that nuclear medicine techniques may be the current gold standard for direct measurements of GFR (inulin and iothalamate), the eGFR obtained using cystatin C does correlate with results from Tc-99m-DTPA renal imaging in sickle cell disease, although with a negative bias, and represents the usual standard of care monitoring in our SCA clinic setting [5] . Additionally, the use of annual cystatin C in our 5-year cohort will provide an internally consistent estimate of GFR. Among participants with SCA screened for 24-h ABPM without regard to clinic hypertension, we identified a large percentage of children with nocturnal hypertension and abnormal nocturnal dipping. Our data have identified that nocturnal hypertension and abnormal uric acid are associated with a lower eGFR. Proven interventions are available for these two risk factors and could be important to prevent the high morbidity and mortality associated with SCA nephropathy. We will continue to follow this cohort for 5 years to better understand a potential relationship between CKD and uric acid or nocturnal hypertension. In addition, we are performing a feasibility trial of losartan to reverse nocturnal hypertension in patients (NCT 02373241).
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